Group items tagged

The European Union's population shrank for a second year running last year, the bloc's statistics office said on Monday, as the region reels from over two million deaths from the coronavirus. According to Eurostat, the population of the 27 countries that make up the bloc fell by close to 172,000 from the previous year and over 656,000 from January 2020. "In 2020 and 2021 the positive net migration no longer compensated for the negative natural change in the EU and, as a consequence, the EU total population has been decreasing," it said, pointing to impacts from the pandemic. The number of deaths began outstripping births in the EU a decade ago, but immigration from outside the bloc helped offset the gap until the first year of the pandemic. The previous time the EU had registered a fall in population was in 2011 - the only other time since 1960 - but this rapidly picked up due to net migration.

North America leads the global heart failure drugs market in 2018 followed by Europe. The US dominates the market owing to the presence of a majority of the heart failure drugs manufacturers in the region. However, the fastest growth rate is anticipated to be in the APAC region due to the presence of large heart failure patient population and availability of wide range of drugs. Most of the revenue is generated from the leading players in the market with dominant sales from Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, Bayer AG, and Pfizer Inc.

Surface disinfectants are chemical formulations that eliminate microorganisms from surfaces or significantly decrease the possibility of their transfer through hand contact between surfaces. These include bedside tables, chairs, walls, floors, and medical equipment (clinical contact surfaces). The global surface disinfectant market is expected to reach USD 789.1 Million by 2022 from USD 529.6 Million in 2017, at a CAGR of 8.3%. Increasing number of surgical procedures, rising geriatric population, and subsequent growth in the prevalence of chronic diseases are the major driving factors for this market.

The global enteral feeding formulas market is estimated to reach USD 5.95 Billion by 2020, growing at a CAGR of 7.6% during the forecast period. The market is mainly driven by the rising incidences of chronic diseases and disorders, the rapidly increasing geriatric population, increasing healthcare expenditure, rising prevalence of preterm births, and increasing demand for homecare. On the other hand, factors such as complications associated with enteral nutrition, patient safety risks, and the risk of feeding and medication errors are some factors that are expected to limit the growth of the enteral feeding formulas market in the coming years.